Evolent Health Inc. (NYSE:EVH) rose 1.9% on Friday . The stock traded as high as $24.76 and last traded at $24.75, with a volume of 151,836 shares changing hands. The stock had previously closed at $24.30.

Several equities research analysts recently issued reports on EVH shares. Zacks Investment Research cut shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Canaccord Genuity restated a “buy” rating on shares of Evolent Health in a report on Friday, May 13th. FBR & Co restated a “buy” rating on shares of Evolent Health in a report on Saturday, May 14th. Leerink Swann restated a “buy” rating and issued a $20.00 target price on shares of Evolent Health in a report on Monday, May 16th. Finally, Jefferies Group started coverage on shares of Evolent Health in a report on Tuesday, July 26th. They issued a “buy” rating and a $28.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $22.50.

The firm’s market cap is $1.50 billion. The firm has a 50-day moving average of $23.86 and a 200 day moving average of $15.50.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. The business earned $56.50 million during the quarter, compared to analysts’ expectations of $51.96 million. Evolent Health’s revenue for the quarter was up 443.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.95) EPS. On average, equities analysts forecast that Evolent Health Inc. will post ($0.54) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Evolent Health stock. Wells Fargo & Company MN raised its stake in Evolent Health Inc. (NYSE:EVH) by 22.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 808,909 shares of the company’s stock after buying an additional 145,685 shares during the period. Wells Fargo & Company MN owned approximately 1.37% of Evolent Health worth $9,796,000 at the end of the most recent quarter.

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.